End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
792,000 KRW | -1.37% |
|
+4.35% | +4.21% |
Jul. 01 | S.Korean shares rise on robust data; battery, biopharma stocks jump | RE |
Jun. 06 | Novartis, Roche, Biogen, Samsung Bioepis in Italy Eye-Medicine Probe | DJ |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 53% by 2026.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- With an expected P/E ratio at 56.99 and 49.03 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+4.21% | 40.77B | A- | ||
+4.14% | 96.32B | A- | ||
-11.86% | 33.21B | B- | ||
+81.24% | 29.36B | A | ||
-14.25% | 15.7B | C | ||
-7.36% | 13.08B | B- | ||
-13.08% | 11.39B | D+ | ||
+176.65% | 10.47B | D | ||
-57.36% | 8.58B | B | ||
+5.32% | 9.08B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- A207940 Stock
- Ratings Samsung Biologics Co.,Ltd.